September 18, 2026
BLA Supports NovaSpira’s Bispecific Antibody NS-342 in Securing Phase I Clinical Trial Approval from South Korea’s MFDS
NovaSpira’s bispecific antibody NS-342 received Phase I clinical trial approval from South Korea’s MFDS, advancing a promising new treatment for advanced liver cancer and GPC3-positive solid tumors.
BLA Supports NovaSpira’s Bispecific Antibody NS-342 in Securing Phase I Clinical Trial Approval from South Korea’s MFDS
NovaSpira's bispecific antibody NS-342 received Phase I clinical trial approval from South Korea's MFDS, advancing a promising new treatment for...
FDA Rare Disease Guidelines 2026 | Frank Li at KIC
Dr. Frank Li of BLA Regulatory will speak at 2026 KIC in Seoul on October 15, sharing recent FDA regulatory...